News Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Market Closed - Nasdaq Stockholm Other stock markets 11:29:59 2024-04-25 am EDT			5-day change	1st Jan Change
5.94 ^SEK	+0.17%		-4.04%	+6.45%

Feb. 22	Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 22	Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	Apr. 24	AQ
Egetis Therapeutics' : 2023 Annual Report published	Apr. 15	PU
Egetis Therapeutics’ 2023 Annual Report published	Apr. 15	AQ
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	Mar. 29	PU
Egetis Therapeutics - Continued progress in Q4	Feb. 23	AQ
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Egetis Therapeutics : – Corporate Presentation December 2023	Dec. 27	PU
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	Dec. 22	AQ
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	Dec. 22	CI
Transcript : Egetis Therapeutics AB - Analyst/Investor Day	Dec. 19
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	Dec. 19	AQ
Egetis’ Investor Day on December 19: Agenda and Registration Details	Dec. 14	AQ
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	Dec. 13	AQ
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	Dec. 13	CI
Save the Date: Egetis to host Investor Day on December 19, 2023	Dec. 01	AQ
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	Nov. 10	MT
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan	Nov. 10	AQ
Egetis Therapeutics - All eyes on eventful 2024	Nov. 09	AQ
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Egetis Therapeutics AB

Equities

EGTX

SE0003815604

Summary

Filters